HomeMarketsSharesGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Trade Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - 0874 CFD

Market is not available at the momentMarket information is presented
as of 2026-09-28T07:46:30+00:00
Trading Conditions
Type
This financial market is available for CFD trading.
Learn more about:CFDs
CFD
Spread0.15
Long position overnight funding adjustment
Long position overnight funding adjustment

Margin. Your investment
HK$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.019152 %
(-HK$3.83)

Trade size with leverage ~ HK$20,000.00

Money from leverage ~ $HK$19,000.00


-0.01915%
Short position overnight funding adjustment
Short position overnight funding adjustment

Margin. Your investment
HK$1,000.00
Overnight funding adjustment
Charges from full value of position
-0.002766 %
(-HK$0.55)

Trade size with leverage ~ HK$20,000.00

Money from leverage ~ $HK$19,000.00


-0.00277%
Overnight funding adjustment time21:00 (UTC)
CurrencyHKD
Min traded quantity10
Margin5.00%
Stock exchangeHong Kong
Commission on trade10%
Guaranteed stop premium
A guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.
1%

1Our charge for executing your trade is the spread, the difference between the buy and sell price. Please consult the Charges and Fees section of our website for further information

Key Stats
Prev. Close12.95
Open13.1
1-Year Change-26.82%
Day's Range13.1 - 13.15

Trade Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited - 0874

About Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd i is engaged in the pharmaceutical and healthcare industry. The Company's segments are Great Southern TCM, Great Commerce, Great Health and Great Medical Care. The Company's Great South TCM includes research, development, manufacturing and sales for Chinese and western medicine, chemical raw medicine, natural drug, biological medicine and intermediates of chemical raw medicine. The Company's Great Health segment includes the research, development, manufacturing and sales of beverages, foods, health products and other products. The Company's Great Commerce segment includes wholesale, retail, import and export for western medicine, Chinese medicine and medical apparatus and instruments. The Great Medical segment is engaged in medical services, traditional Chinese medicine health preservation, modern pension and medical equipment industry.

Financial summary

BRIEF: For the fiscal year ended 31 December 2021, Guangzhou Baiyunshan Phrmcl Hldgs Co Ltd revenues increased 12% to RMB69.01B. Net income increased 28% to RMB3.72B. Revenues reflect Business segment increase of 8% to RMB46.89B, Health segment increase of 38% to RMB10.87B, Foreign segment increase of 7% to RMB42.8M. Net income benefited from Change in Fair value decrease from RMB8.5M (expense) to RMB196.9M (income).

Latest shares articles

Cellnex stock forecast
Cellnex stock forecast: BlackRock raises stake to 6.398%
Cellnex Telecom is a European telecom-infrastructure company listed in Madrid. In September, BlackRock raised its stake to 6.398% as Cellnex continued its share-buyback programme. Explore third-party CNLX price targets Past performance is not a reliable indicator of future results.
8 hours ago
Siemens stock forecast
Siemens stock forecast: VinSpeed high-speed rail contract
Siemens is a German industrial group with businesses across automation, infrastructure and mobility. On 22 September 2026, Siemens Mobility signed a high-speed rail contract with VinSpeed. Explore third-party SIE price targets. Past performance is not a reliable indicator of future results.
9 hours ago
DeFi Technologies stock forecast
DeFi Technologies stock forecast: Valour hedge fund launch
DeFi Technologies' subsidiary Valour launched its first hedge fund on 21 September 2026, expanding the business beyond exchange-traded products. Explore third-party DEFT price targets and technical analysis. Past performance is not a reliable indicator of future results.
10 hours ago
Buzzi Unicem logo displayed on a smartphone with a financial market chart in the background.
Buzzi stock forecast: H1 EBITDA and margin pressure
Buzzi is an Italian building-materials group listed in Milan, with recent trading shaped by a September share-price decline and a new investor presentation. Explore third-party BZU price targets and technical analysis. Past performance is not a reliable indicator of future results.
11:07, 25 September 2026

User feedback and ratings

Showing our 4 & 5 star reviews. The specific details of the user have been intentionally anonymised to safeguard their privacy pursuant to GDPR requirements.

Ready to join a leading broker?

1. Create your account2. Make your first deposit3. Start when you’re ready